Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Tax Provisions (2023 - 2025)

Entrada Therapeutics (TRDA) has 3 years of Tax Provisions data on record, last reported at $124000.0 in Q4 2025.

  • For Q4 2025, Tax Provisions rose 106.78% year-over-year to $124000.0; the TTM value through Dec 2025 reached $924000.0, up 2.67%, while the annual FY2025 figure was $924000.0, 2.67% up from the prior year.
  • Tax Provisions reached $124000.0 in Q4 2025 per TRDA's latest filing, down from $600000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $18.7 million in Q4 2023 and bottomed at -$17.4 million in Q3 2023.
  • Average Tax Provisions over 3 years is $1.9 million, with a median of $600000.0 recorded in 2025.
  • Peak YoY movement for Tax Provisions: crashed 109.76% in 2024, then soared 132.07% in 2025.
  • A 3-year view of Tax Provisions shows it stood at $18.7 million in 2023, then plummeted by 109.76% to -$1.8 million in 2024, then soared by 106.78% to $124000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were $124000.0 in Q4 2025, $600000.0 in Q3 2025, and $200000.0 in Q2 2025.